{"name":"Jazz Pharmaceuticals plc","slug":"jazz","ticker":"JAZZ","exchange":"NASDAQ","domain":"jazzpharma.com","description":"Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.","hq":"Dublin, Ireland","founded":0,"employees":"2890","ceo":"Bruce Cozadd","sector":"Specialty Pharma","stockPrice":194.12,"stockChange":3.18,"stockChangePercent":1.67,"marketCap":"$12.0B","metrics":{"revenue":4200000000,"revenueGrowth":10.1,"grossMargin":91.7,"rdSpend":299726000,"netIncome":-356148000,"cash":2441899008,"dividendYield":0,"peRatio":7.8,"fiscalYear":"FY2018"},"revenueBreakdown":[],"timeline":[{"date":"1989-01-01","label":"Clozaril first approved","drug":"Clozaril","drugSlug":"clozapine","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Zepzelca first approved","drug":"Zepzelca","drugSlug":"lurbinectedin","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-05-01","label":"Clozaril patent expiry (Formulation)","drug":"Clozaril","drugSlug":"clozapine","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"Xyrem patent cliff ($1.1B at risk)","drug":"Xyrem","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"Sunosi patent cliff ($200M at risk)","drug":"Sunosi","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Dociparstat","genericName":"Dociparstat","slug":"dociparstat","indication":"Other","status":"discontinued"},{"name":"Rapydan","genericName":"Rapydan","slug":"rapydan","indication":"Other","status":"marketed"},{"name":"Xyrem","genericName":"Xyrem","slug":"xyrem","indication":"Cataplexy and narcolepsy","status":"marketed"},{"name":"pegcrisantaspase","genericName":"pegcrisantaspase","slug":"pegcrisantaspase","indication":"Other","status":"phase_2"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Clozaril","genericName":"CLOZAPINE","slug":"clozapine","indication":"Suicidal Behavior in Schizoaffective Disorder","status":"marketed"},{"name":"Sativex","genericName":"Sativex","slug":"sativex","indication":"Muscle Spasticity due to Multiple Sclerosis","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"infectious","drugs":[{"name":"Zepzelca","genericName":"LURBINECTEDIN","slug":"lurbinectedin","indication":"Small cell carcinoma of lung","status":"marketed"},{"name":"Zepzelca","genericName":"Zepzelca","slug":"zepzelca","indication":"Small cell carcinoma of lung","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Marinol","genericName":"Marinol","slug":"marinol","indication":"Anorexia from HIV","status":"marketed"}]},{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"ODSH at 0.125 mg/kg/h","genericName":"ODSH at 0.125 mg/kg/h","slug":"odsh-at-0-125-mg-kg-h","indication":"Protein-Losing Enteropathy Secondary to Single Ventricle","status":"discontinued"}]}],"pipeline":[{"name":"Dociparstat","genericName":"Dociparstat","slug":"dociparstat","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Clozaril","genericName":"CLOZAPINE","slug":"clozapine","phase":"marketed","mechanism":"Clozapine's efficacy in schizophrenia may be due to its antagonism of D2 and 5-HT2A receptors.","indications":["Suicidal Behavior in Schizoaffective Disorder","Suicidal Behavior in Schizophrenia","Treatment-Resistant Schizophrenia"],"catalyst":""},{"name":"Marinol","genericName":"Marinol","slug":"marinol","phase":"marketed","mechanism":"N-arachidonyl glycine receptor, Cannabinoid receptor 2, Fatty-acid amide hydrolase 1","indications":["Anorexia from HIV","Chemotherapy-induced nausea and vomiting"],"catalyst":""},{"name":"ODSH at 0.125 mg/kg/h","genericName":"ODSH at 0.125 mg/kg/h","slug":"odsh-at-0-125-mg-kg-h","phase":"discontinued","mechanism":"ODSH is a modified chitosan polymer that binds intestinal lymphatic proteins to reduce protein loss in enteropathy.","indications":["Protein-Losing Enteropathy Secondary to Single Ventricle"],"catalyst":""},{"name":"Rapydan","genericName":"Rapydan","slug":"rapydan","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Sativex","genericName":"Sativex","slug":"sativex","phase":"marketed","mechanism":"Small molecule","indications":["Muscle Spasticity due to Multiple Sclerosis"],"catalyst":""},{"name":"Xyrem","genericName":"Xyrem","slug":"xyrem","phase":"marketed","mechanism":"Calcium/calmodulin-dependent protein kinase type II subunit alpha, GABA-B receptor, Gamma-hydroxybutyrate receptor","indications":["Cataplexy and narcolepsy","Narcolepsy"],"catalyst":""},{"name":"Zepzelca","genericName":"LURBINECTEDIN","slug":"lurbinectedin","phase":"marketed","mechanism":"Zepzelca works by attaching an alkyl group to DNA, which interferes with DNA replication and causes cell death.","indications":["Small cell carcinoma of lung"],"catalyst":""},{"name":"Zepzelca","genericName":"Zepzelca","slug":"zepzelca","phase":"marketed","mechanism":"Small molecule","indications":["Small cell carcinoma of lung"],"catalyst":""},{"name":"pegcrisantaspase","genericName":"pegcrisantaspase","slug":"pegcrisantaspase","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Jazz Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Jazz Pharmaceuticals reported fourth quarter and full year 2023 financial results, with net sales of $1.1 billion and a net loss of $0.1 billion.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Jazz Pharmaceuticals Announces Agreement to Acquire GW Pharmaceuticals","summary":"Jazz Pharmaceuticals announced an agreement to acquire GW Pharmaceuticals, a UK-based biopharmaceutical company, for $7.2 billion.","drugName":"","sentiment":"positive"},{"date":"2023-08-18","type":"regulatory","headline":"FDA Approves Sunosi for Excessive Daytime Sleepiness in Adults with Narcolepsy","summary":"The US FDA approved Sunosi, a wake-promoting agent, for the treatment of excessive daytime sleepiness in adults with narcolepsy.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxQWlBma2Faekg5cUtiY0hLN2Vvc0xOWXM1MFZFT1ZXclVDalV2NGJ5aV81Z1FLZUNZZEltYW01N3RDd3F6LWNINDhZV1lHV0FkR3dpeUcwN1BtSkVEY2pic2dtR0RESlFhdklsd29zYUpOelkyaVlHU3JyZjFHTTJ2YTJMaVZOTFJfVHRnOWotTGFNNUdKU2pIcVRKSTNCd2pfN2FDMjJFeEg1d0JKb21GcDhoYVFCNHh2M0MtODRBU1ltaXFiOG1zeThhMms?oc=5","date":"2026-04-01","type":"pipeline","source":"PR Newswire","summary":"Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference - PR Newswire","headline":"Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOWE83akQ0T1dIWHN4dzA5b0xfVzhJakFTUjEwRkFGakxBM3FWQ2xuTFZEdzV4MFVMTVNFakFYaVdXck1ESkc4R3RMbWR3eEktWnprbG5ERThPUTlKV3RrejhGQ25QOUJ5cXFDLUZFZWpBSk94YzdvUXZOSFN4cG5IeGFMVzVnOFhiRTBnUEhmV2EtMWIwdW9IYzZOdG9fdlNLRkcwWVBTNmZHUlRYeFhhc3FfcURzbm8?oc=5","date":"2026-03-24","type":"pipeline","source":"Stock Titan","summary":"People with sleep disorders to get guidance on sodium, heart risk - Stock Titan","headline":"People with sleep disorders to get guidance on sodium, heart risk","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxOdjk1NllYaTBoalNwVUdnaDNOT3B5MFlMY1hfbDJiZVZWQS1seklZaWpjZHVCamFqRXhqSENSVlAzN0hBNWFsakJnazRQVW1XX3JSOE9ldTVKUWVicGVORy01NnlGVVdKRzEzTlhTMWYwUUYxYlp6Qi05Q3dMMndOV2ZXTXI1b19VSVZFV3VHUUoxcFNBcXVrcll0V2FNWDZTeFlsT1RsZWtfWjFnYmxzX1dFMzhkaC1aQVQwSlRPdUUwVzZDRy05Um9vaVptdXkyekNNSjJiV1ZkdTFiNzJFQVF1b1VrRXF0YzNNZ2lyNlRXS0FuUGhCYURQM0lNTkE?oc=5","date":"2026-03-18","type":"trial","source":"PR Newswire","summary":"Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026 - PR Newswire","headline":"Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxPOGJNd2hLUFRucUVUNTBDSGg1azlmdUdHQkRUN2JFX01TZDBMemhmbWp3SHdPWHVtQi1IdUJ0cEItdzRaY1FuVnlFUEpPOXhLaGFiTER5dzV3NFVTeng3ZHNzczQxUE5OWlRFS1NraU1FODVlN3pnRGp2WlBOWVRIYlozbHhpYVRoWUxGMTNyamMwOTJ1SkxwdmhwaVBvb3VPQ2RTYzZrbXNBTDhoS0gwQm44WXVMbEdaTERQSlpDZU5SeVc2ak1iWC1mZEx4N042NjlFd3Zvc0ZaQQ?oc=5","date":"2026-03-12","type":"pipeline","source":"MarketBeat","summary":"Crossmark Global Holdings Inc. Sells 10,433 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat","headline":"Crossmark Global Holdings Inc. Sells 10,433 Shares of Jazz Pharmaceuticals PLC $JAZZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQVjlNZVFXQjVnLU4wYXZ1a3Z0N090djBUb0x5akVPWXU1OXBrd3pWM2lOa0lRdlU2bThvTktMZnJsc2dpSmZDb0Q0WklWZlBnVTg5VmVEaHI0bVM0cUJQWllIQXltcEVFNXF6ZEdsS2tWQWNZejU0RWo0LWJkcDNBQ2VUNE1oTHRiZEkzaFkyNnkzUXBHcTQwczFVazZBZTNGSUFiYTViR3BLOHpScmZFalFFYm85alIxeGc?oc=5","date":"2026-03-02","type":"pipeline","source":"Stock Titan","summary":"Jazz Pharmaceuticals (NASDAQ: JAZZ) grants 14,822 RSUs to R&D leader - Stock Titan","headline":"Jazz Pharmaceuticals (NASDAQ: JAZZ) grants 14,822 RSUs to R&D leader","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQUTl5NE1hcXB3djJKRmZSelM0YUhKbXNyXy1zbWpwTlRjQlBINWNZOVVCbUJDWjFjMnFLS2FneFp4UE52MTNXR0ZwaktlaEFDaXNzM09CcDd6LXBvSWxiZ2tvQVJudlo5aVdSSVUydUFlcUFRa3h5QnY5eS1iejNRN0I4UzJIOHlGMGlLX21MczhDYjkyNDB1NzJjQzNrRTl2aFpOYTlLMDR4b1JjWlhXelZmUVlWRS1zQnpCLTBsczZyb2FDYmk1aHRuSE1jMjFrV3h3eExfalRvb0RwREh5djNRTC01WHF3T2V3ZUVwVnZqQk14emFjTEdyZ3FKRFZCWVVpM2dn?oc=5","date":"2026-02-24","type":"earnings","source":"PR Newswire","summary":"Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance - PR Newswire","headline":"Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPTzVBdFhteWdTa3pkM1M0Q0FpcG52bmUtQXN6TzdHY0pSOVR0emFST3c5VU5lWEZoaGhaOGY4Vk4zMFY0djluRklKdTFxdFlSNVJfeFlyeW9RNlZwdlQweHhlNGdfLUFnMlpzaUhyLVFyUlBoQ2RWWnRLNXA1emtPNFlmZDBJUDg1blZoc1c3WEFndG9LUC1CRjRXT3c0ZnEybG83NHBvV1VMQXRSZFhWWA?oc=5","date":"2026-02-17","type":"pipeline","source":"Stock Titan","summary":"Jazz Pharma to stream March investor conference talks - Stock Titan","headline":"Jazz Pharma to stream March investor conference talks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQMGtGVzF4UFUxZ2ZlcnVPV2JXSGhybnR3UUgwX0R5OS1FdFlJZHRZWjluS25rY0V4RGxiUWtpaG93LWJkMzlHZ3I1a3k4LTBhcHNXVFR5THdvakZwTFJPRFc2ZmFGTktxNGlWQk9FT25Vc1F3WmxKTnFHOWJreVFpOFJIdEdlYy1OLVdnUjI2QnRHR3hUQnVaT3BSWHdQejFkYjROVlJySnFZWXpZNlBSd1RPVmhoemlOVi1SUFh2MXh3QQ?oc=5","date":"2026-02-17","type":"pipeline","source":"PR Newswire","summary":"Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences - PR Newswire","headline":"Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxNWWJKWnVQMFE1ZWdsN2tNdEplOUtMbmw5amJvZnJYRWNjSTNvSHY3OXhlSm5BVFN1U3ZKWEJwLTJaWUYwa0xkTWNLZjBRaTZMQ1NaWkk3cGRNWkdIZk5CVUFyU0w3UFh2X1cyU3VqY0lqZlUyLTBndmREUzZNSTFWZW8zSzM0RnZOUE9FV3RXTjBuZEpQQ01pUjE0LVg4enQxWnpzdm1uNzR3MTR1TGZuUUM0dmlTT3RBaDIzVjdUSWtZNW5DdU15QkM1czJjNzhGTjJMM2psTUxIOGhENzZ3MThOb2Y2bkYwZ2Q1MGNXV0NyNnh6ZlNzaGpBaDg?oc=5","date":"2026-02-10","type":"earnings","source":"PR Newswire UK","summary":"Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026 - PR Newswire UK","headline":"Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNT1FmRF9kcmgzczR2NkYxRldPTGN5SFdyanZpVWJsWE9xVXQ2SFdFNEt2WG0ycGxKbDF5UTBONHU1dElpZlRRaTNKbUxfM19jWDdCNmZsQm5EWW5Mb0VmYm5KQmZ4OWxoeDlEb2V3ajk0S1dwRmMyODRSYk9Ua1V4R2lmRVUzZms3Z3pVWVZrTXlFXzkxVWhEcXI3U0FSQjk2YnFadXhn?oc=5","date":"2026-01-09","type":"deal","source":"Seeking Alpha","summary":"Jazz Pharmaceuticals: A Strong Buy Due To Execution In Oncology (NASDAQ:JAZZ) - Seeking Alpha","headline":"Jazz Pharmaceuticals: A Strong Buy Due To Execution In Oncology (NASDAQ:JAZZ)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-18","type":"earnings","source":"simplywall.st","summary":"Improved Revenues Required Before Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock's 25% Jump Looks Justified - simplywall.st","headline":"Improved Revenues Required Before Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock's 25% Jump Looks Justified","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE1YNWdHeG1nUllPVWV0ZmVSdVVDaXZ3V0JQcDRVRWFOa1VqSmdGd1c2LUR5eUlrREMyZU1FTkF0YjBHS2c0WDhOMG5vdEUtYjhGVG9DZ1c5OEN0TlZEQlk3TDVQN0ZDMFhSMnphLVNEREdzRG9pSUUtdkdkaWNTdw?oc=5","date":"2025-11-17","type":"trial","source":"Yahoo Finance","summary":"Jazz Pharma (JAZZ) Hits Fresh 52-Week High on Strong Cancer Treatment Trial - Yahoo Finance","headline":"Jazz Pharma (JAZZ) Hits Fresh 52-Week High on Strong Cancer Treatment Trial","sentiment":"neutral"}],"patents":[{"drugName":"Clozaril","drugSlug":"clozapine","patentNumber":"8057811","type":"Formulation","expiryDate":"2028-05-01","territory":"US","genericFilings":[]},{"drugName":"Xyrem","drugSlug":"sodium-oxybate","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1100000000},{"drugName":"Sunosi","drugSlug":"solriamfetol","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":200000000}],"drugCount":10,"phaseCounts":{"discontinued":2,"marketed":7,"phase_2":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Pfizer","GSK","Biogen"],"therapeuticFocus":["Neurology","Hematology"],"financials":{"source":"sec_edgar+yahoo","revenue":476457000,"revenuePeriod":"2018-12-31","revenueHistory":[{"value":476457000,"period":"2018-12-31"},{"value":469373000,"period":"2018-09-30"},{"value":500479000,"period":"2018-06-30"},{"value":444613000,"period":"2018-03-31"},{"value":1618693000,"period":"2017-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":299726000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-356148000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":11659340000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":2890,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":194.12,"previousClose":190.94,"fiftyTwoWeekHigh":198,"fiftyTwoWeekLow":95.49,"fiftyTwoWeekRange":"95.49 - 198.0","fiftyDayAverage":177.44,"twoHundredDayAverage":147.85,"beta":0.23,"enterpriseValue":14739740672,"forwardPE":7.8,"priceToBook":2.76,"priceToSales":2.8,"enterpriseToRevenue":3.45,"enterpriseToEbitda":8.6,"pegRatio":0.6,"ebitda":1714366976,"ebitdaMargin":40.2,"freeCashflow":1354607872,"operatingCashflow":1355773056,"totalDebt":5427305984,"debtToEquity":125.7,"currentRatio":1.86,"returnOnAssets":5.4,"returnOnEquity":-8.5,"analystRating":"1.6 - Buy","recommendationKey":"buy","numberOfAnalysts":16,"targetMeanPrice":223.5,"targetHighPrice":275,"targetLowPrice":188,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":3.1,"institutionHeldPercent":102.9,"sharesOutstanding":61560350,"floatShares":59618737,"sharesShort":6164020,"shortRatio":5.49,"shortPercentOfFloat":10,"epsTrailing":-5.84,"epsForward":25.01,"revenuePerShare":69.98,"bookValue":70.3,"officers":[{"age":61,"name":"Mr. Bruce C. Cozadd","title":"Co-Founder & Chairman"},{"age":53,"name":"Ms. Renee D. Gala","title":"President, CEO & Director"},{"age":60,"name":"Mr. Philip L. Johnson","title":"Executive VP & CFO"},{"age":53,"name":"Ms. Patricia  Carr","title":"Senior VP & Chief Accounting Officer"},{"age":58,"name":"Dr. Robert  Iannone M.D.","title":"Executive VP, Chief Medical Officer and Global Head of Research & Development"},{"age":58,"name":"Ms. Samantha  Pearce","title":"Executive VP & Chief Commercial Officer"},{"age":null,"name":"Jack W. Spinks","title":"Executive Director of Investor Relations"},{"age":49,"name":"Ms. Neena M. Patil J.D.","title":"Executive VP & Chief Legal Officer"}],"industry":"Biotechnology","irWebsite":"http://investor.jazzpharma.com/phoenix.zhtml?c=210227&p=irol-irhome","website":"https://www.jazzpharma.com","phone":"353 1 634 7800"}}